Bullish Trend Analysis Report: Petroleo Brasileiro Petrobras, XOMA Corp, Groupon Inc, EnteroMedics Inc, Schlumberger Limited

   Bullish Trend Analysis Report: Petroleo Brasileiro Petrobras, XOMA Corp,
             Groupon Inc, EnteroMedics Inc, Schlumberger Limited

PR Newswire

NEW YORK, December 4, 2013

NEW YORK, December 4, 2013 /PRNewswire/ --

Market Buzz Report, an online penny stock community, issues stock analysis for
Petroleo Brasileiro Petrobras SA (NYSE:PBR), XOMA Corp (NASDAQ:XOMA), Groupon
Inc (NASDAQ:GRPN), EnteroMedics Inc (NASDAQ:ETRM), Schlumberger Limited
(NYSE:SLB).

Petroleo Brasileiro Petrobras SA (NYSE:PBR) plunged 11% after Friday's
announcement of a 4% price rise for gasoline and 8% for diesel, but "for
commercial reasons, the parameters of the pricing methodology will be strictly
internal to Petrobras." Raymond James analysts also say the guidelines on the
pricing methodology are confusing, with two seemingly contradictory
objectives: The first is to "reach, in a compatible time period, the alignment
between Brazilian and international prices," while the second is to "prevent
transferring the volatility of international prices to the domestic consumer."

Free Urgent Insider Catalyst Report For PBR Available
Here:http://marketbuzzreport.com/index.php?code=PBR(Or Copy and paste the
URL into your browser)

Analysts weigh in very negatively on Petrobras timid fuel price increases and
opaque pricing methodology. Credit Suisse downgrades shares all the way to
Sell from Buy, citing a lack of management credibility and the lack of a
business friendly government in Brazil after Friday's announcement. PBR wants
to reduce its debt burden to below 2.5x net debt to EBITDA but for that to
happen, Credit Suisse notes it must raise its fuel price by 20% in 2015, which
has not been done before. The market is concerned that this could be the last
price increase until the 2014 presidential election, Deutsche Bank adds.

XOMA Corp(NASDAQ:XOMA) could be in for a big post-Thanksgiving move today
based on news that the biotech-focused hedge fund Baker Brothers has been
snapping up the company's shares as of late. Specifically, the fund now owns
more than $100 million in XOMA, and their optimism has paid off handsomely so
far this year. Based on the positive clinical development of the company's
lead antibody gevokizumab in a wide variety of inflammatory conditions, XOMA
shares have nearly doubled year to date.

Free Urgent Insider Catalyst Report For XOMA Available Here:
http://marketbuzzreport.com/index.php?code=XOMA(Or Copy and paste the URL
into your browser)

Although this rise has certainly been impressive, the best may be yet to come.
A few weeks ago, XOMA announced compelling proof-of-concept data from two
different studies for gevokizumab. During the initial data release, XOMA said
it'll move forward with plans to conduct a late-stage trial for gevokizumab as
a treatment for pyoderma gangrenosum, a rare type of skin ulcer. And recently,
XOMA decided to go forward with a second late-stage trial to study the
antibody in erosive osteoarthritis of the hand.

Groupon Inc (NASDAQ:GRPN) reports its North American billings for the four-day
Thanksgiving weekend were up 30% Y/Y. The company adds 55% of those
transactions took place via mobile devices. (PR) The billings growth rate is
soundly above the 20% North American gross billings growth Groupon reported
for Q3, and even with the 30% clip it reported for Q2. The share of N.A.
transactions coming via mobile appears to be up slightly from Q3, during which
time mobile accounted for "over 50%" of buying activity. Amazon and eBay also
saw strong weekend sales.

Free Urgent Insider Catalyst Report For GRPN Available Here:
http://marketbuzzreport.com/index.php?code=GRPN(Or Copy and paste the URL
into your browser)

Shares of EnteroMedics Inc(NASDAQ:ETRM) were holding onto this morning's big
gains - and then some.

Count Northland Capital's Suraj Kalia among those who think the stock has
further to run. "Based on the current 18-month data, and barring any
unforeseen kinks in any subgroup analysis (only top-line data has been
released so far), we do not envision a mixed or negative ruling in an FDA
panel," Kalia says, referencing the pivotal VBLOC study.

Northland's target is $7 and although Kalia says that the firm "can articulate
on DCF's as to how [the] price target was achieved ... ETRM could now be a
good takeout target post-approval."

Free Urgent Insider Catalyst Report For ETRM Available Here:
http://marketbuzzreport.com/index.php?code=ETRM(Or Copy and paste the URL
into your browser)

Schlumberger Limited (NYSE:SLB) says it expects the temporary shutdown of its
operations in southern Iraq last month in a security incident to reduce Q4
profits ~2%, impacting EPS $0.02-$0.03; the average analyst earnings estimate
for the quarter is $1.37/share. SLB says activity has nearly returned to
normal at the location, and expects continued strong growth in Iraq next year,
SLB's president of operations and integration tells an investor conference.
Otherwise, SLB reiterates expectations for spending growth in 2014,
particularly in the Gulf of Mexico, sub-Saharan Africa, Russia, the Middle
East and China.

Free Urgent Insider Catalyst Report For SLB Available Here:
http://marketbuzzreport.com/index.php?code=SLB(Or Copy and paste the URL
into your browser)

USMarketBuzz.com is an investment community that Focuses on MicroCap
Securities. USMarketBuzz.com is an authorative authentic Google News Site and
Leading Provider of Investment Awareness and Featured Company Profiles. If you
would like more information regarding our news coverage solutions, please
visit http://www.USMarketBuzz.com/for more details. Get an edge on the market
with our Premium News Alertsthat are FREE for a limited time at
http://www.USMarketBuzz.com/. Follow us on Facebook:
https://www.facebook.com/usmarket.buzz. Sign up for our FREE SMS News alerts
delivered directly to your mobile phone by texting the word PREPROMO to 27126.
(SMS alerts are free, however data rates may apply, check your wireless plan
for details.)

DISCLAIMER: FNNewswire (FNNW) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNNW is NOT affiliated in any manner
with MarketBuzz Reports, USMarketBuzz.com or any company mentioned herein.
The commentary, views and opinions expressed in this release by MarketBuzz
Reports and USMarketBuzz.com are solely those of the MarketBuzz Reports &
USMarketBuzz.com and are not shared by and do not reflect in any manner the
views or opinions of FNNW. The companies that are discussed herein may or may
not have approved the statements made in this release. FNNW is not liable for
any investment decisions by its readers or subscribers FNNW and its affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT a registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any security. FNNW
was not compensated by any public company mentioned herein to disseminate this
press release.

FNNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNNW undertakes no obligation to update such statements.

FNNW Contact Information:
Company: FN Newswire
Contact email: editor@fnnewswire.com
U.S.Phone: +1(954)345-0611

SOURCE FN Media Group, LLC
 
Press spacebar to pause and continue. Press esc to stop.